NeoLight reaches agreement to acquire InterVIEW Medical Systems, globally recognized provider of ROP education and examination

NeoLight has signed a binding agreement to acquire key assets of interVIEW Medical Systems ROP (retinopathy-of-prematurity)  risk management education course and ROP risk management clinical exam, collectively called the ROP Certification Program.

The interVIEW Medical System ROP Certificate Program is recognized as a premier course for ROP training by OMIC, the largest insurer of ophthalmologists in the United States, and by the American Academy of Ophthalmology. interVIEW Medical has been the source of ROP education and certification for over 60% of all practicing pediatric ophthalmologists and retina specialists in the United States. The certification program was put together by industry thought leaders – Dr.Michael Trese, Dr. Antonio Capone, Dr. Kim Drenser and Dr. Carl Park.

“The interVIEW Medical System ROP Certificate Program has proven to be the leading source of ROP education and certification in the United States” said Vivek Kopparthi, NeoLight’s Co-founder & CEO “We look forward to advancing this great tool to allow more clinicians access to this powerful resource.”

“This course was founded to enable clinicians to be able to have a stronger safety net and an effective set of guidelines – all directed towards maximizing clinical outcomesfor infants at risk for ROP. The ROP Education material is free of cost and isupdated to the latest ICROP3 guidelines. “ said Dr. Antonio Capone, one of thefounders of interview medical.

The interVIEWMedical System ROP Certificate Program set the standard for ROP Education andExams by focusing on leading ROP guidance including the latest ICROP3 and AAPstandards. NeoLight is focused on implementing improvements and responding tothe needs of the interVIEW Medical customers and will continue to work with interVIEWMedical founding physicians Antonio Capone MD and Kimberly Drenser, MD PhD ofAssociated Retinal Consultants, MI.


NeoLight is amedical device company that develops empathy driven, best-in-class technologiesfor treating preventable conditions in the newborn care market. Empathy drivensolutions are a framework that has the doctor-nurse-mother-infant ecosystem atthe center. It fosters the emotional connection that happens, thereby providingnot just treatment but also providing care. Driving neonatal care beyond thetraditional hospital setting, NeoLight is also creating a robust home market totreat neonatal conditions in the home. To learn more, visit and follow us on TwitterLinkedIn, and Facebook.



Posted in AZBio News.